VEGF-C in non-small cell lung cancer: meta-analysis
- PMID: 24144865
- DOI: 10.1016/j.cca.2013.10.002
VEGF-C in non-small cell lung cancer: meta-analysis
Abstract
Background: We sought to clarify the prognostic value of vascular endothelial growth factor C (VEGF-C) in survival of patients with non-small cell lung cancer (NSCLC).
Methods: We performed a meta-analysis of relevant literature to aggregate the available survival results, using studies published in English until May 2013. Eligible studies dealt with VEGF-C assessment in NSCLC patients on primary lesions and reported survival data according to VEGF-C expression.
Results: We aggregated 16 trials, comprising 1988 patients, in this meta-analysis. The overall combined hazard ratio (HR) was 1.65 (95% confidence interval (CI): 1.37-1.98) and was calculated using a random-effects model. It associated high VEGF-C expression with poor survival in all NSCLC patients, including those with stage I NSCLC and high VEGF-C expression (HR: 2.00; 95% CI: 1.22-3.28). However, VEGF-C expression did not significantly correlate with survival in patients with lung adenocarcinoma (ADC) (HR: 1.48; 95% CI: 1.01-2.18).
Conclusion: Our meta-analysis shows that VEGF-C expression is associated with poor prognosis for NSCLC patients, including patients with stage I NSCLC. However, VEGF-C expression is not significantly correlated with survival for patients with lung ADC.
Keywords: Hazard ratio; Meta-analysis; Non-small cell lung cancer; Prognosis; Vascular endothelial growth factor C.
© 2013.
Similar articles
-
Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysis.Clin Chim Acta. 2015 Dec 7;451(Pt B):208-14. doi: 10.1016/j.cca.2015.01.023. Epub 2015 Feb 4. Clin Chim Acta. 2015. PMID: 25661085 Review.
-
A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.Eur J Surg Oncol. 2014 Mar;40(3):311-7. doi: 10.1016/j.ejso.2013.11.012. Epub 2013 Dec 4. Eur J Surg Oncol. 2014. PMID: 24332948 Review.
-
Cox-2 in non-small cell lung cancer: a meta-analysis.Clin Chim Acta. 2013 Apr 18;419:26-32. doi: 10.1016/j.cca.2013.01.012. Epub 2013 Feb 4. Clin Chim Acta. 2013. PMID: 23384501
-
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.Lung Cancer. 2009 Dec;66(3):314-8. doi: 10.1016/j.lungcan.2009.02.013. Epub 2009 Mar 25. Lung Cancer. 2009. PMID: 19324448
-
Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.Cancer. 2003 Jan 15;97(2):457-64. doi: 10.1002/cncr.11073. Cancer. 2003. PMID: 12518370
Cited by
-
MiR-210 regulates lung adenocarcinoma by targeting HIF-1α.Heliyon. 2023 May 6;9(5):e16079. doi: 10.1016/j.heliyon.2023.e16079. eCollection 2023 May. Heliyon. 2023. PMID: 37215862 Free PMC article.
-
Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer.J Clin Med. 2023 Mar 21;12(6):2412. doi: 10.3390/jcm12062412. J Clin Med. 2023. PMID: 36983412 Free PMC article. Review.
-
Uses of Vascular Endothelial Growth Factor C as a Lung Adenocarcinoma Prognostic Biomarker.World J Oncol. 2023 Feb;14(1):51-59. doi: 10.14740/wjon1520. Epub 2023 Feb 26. World J Oncol. 2023. PMID: 36896001 Free PMC article.
-
Intercellular Communication-Related Molecular Subtypes and a Gene Signature Identified by the Single-Cell RNA Sequencing Combined with a Transcriptomic Analysis.Dis Markers. 2022 May 16;2022:6837849. doi: 10.1155/2022/6837849. eCollection 2022. Dis Markers. 2022. PMID: 35620271 Free PMC article.
-
Coexpression of TLR9 and VEGF-C is associated with lymphatic metastasis in prostate cancer.Asian J Androl. 2022 Jul-Aug;24(4):380-385. doi: 10.4103/aja202167. Asian J Androl. 2022. PMID: 34643549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
